| __timestamp | BioCryst Pharmaceuticals, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 1499100000 |
| Thursday, January 1, 2015 | 13047000 | 1923500000 |
| Friday, January 1, 2016 | 11253000 | 2351400000 |
| Sunday, January 1, 2017 | 13933000 | 2564000000 |
| Monday, January 1, 2018 | 29514000 | 2397300000 |
| Tuesday, January 1, 2019 | 37121000 | 2503400000 |
| Wednesday, January 1, 2020 | 67929000 | 3344600000 |
| Friday, January 1, 2021 | 118818000 | 4529200000 |
| Saturday, January 1, 2022 | 159371000 | 4179100000 |
| Sunday, January 1, 2023 | 213894000 | 4650100000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. Over the past decade, Viatris Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses.
Viatris Inc., a global healthcare giant, has consistently maintained high SG&A expenses, peaking at approximately $4.65 billion in 2023. This represents a steady increase of over 200% since 2014, reflecting its expansive operational scale and market reach. In contrast, BioCryst Pharmaceuticals, a smaller biotech firm, has seen its SG&A expenses grow from $7.5 million in 2014 to $214 million in 2023, marking a staggering 2800% increase. This surge underscores BioCryst's aggressive growth and investment in market penetration.
These trends highlight the diverse approaches to cost management within the pharmaceutical sector, offering valuable insights for investors and industry analysts alike.
Cost Management Insights: SG&A Expenses for Novartis AG and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Genmab A/S vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
BioCryst Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?